GlassScriptPhysician profile
Juliann S Wallner
NPI 1265546386
$6,873.43
in general payments reported to CMS, 2019-2025
35 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $298 · 2021: $348 · 2022: $584 · 2023: $1,003 · 2024: $1,836 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,111.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,500.49 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $457.22 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $446.77 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $392.63 | 2019-2025 | Libtayo, Dupixent |
| Galderma Laboratories, L.P. | $374.36 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Genzyme Corporation | $374.29 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $360.59 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $327.04 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $324.13 | 2019-2024 | |
| Amgen INC. | $273.26 | 2020-2025 | Otezla |
| Incyte Corporation | $230.34 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $205.06 | 2019-2025 | Anzupgo, Adbry |
| Arcutis Biotherapeutics, INC. | $198.38 | 2023-2025 | Zoryve |
| Ucb, INC. | $177.49 | 2023-2025 | Bimzelx, Cimzia |
| Biofrontera INC. | $170.58 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $164.24 | 2023-2025 | Puraply, Via Matrix |
| Lilly USA, LLC | $139.64 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Almirall LLC | $98.11 | 2019-2023 | Klisyri |
| Mayne Pharma Commercial LLC | $70.14 | 2019 | |
| Allergan, INC. | $68.76 | 2020-2021 | |
| Dusa Pharmaceuticals, INC. | $67.04 | 2019 | |
| Celgene Corporation | $56.13 | 2019 | |
| Organon LLC | $47.81 | 2025 | Vtama |
| Dermira, INC. | $45.81 | 2019 | |
| Journey Medical Corporation | $44.26 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $39.13 | 2024 | Ycanth |
| Aclaris Therapeutics, INC. | $38.93 | 2019 | |
| Prugen, INC. Pharmaceuticals | $30.32 | 2019 | |
| Vyne Pharmaceuticals INC. | $27.42 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.82 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.06 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.39 | 2020 | |
| Stemline Therapeutics INC. | $18.61 | 2019 | |
| Botanix Sb INC | $18.39 | 2025 | Sofdra |
| Promius Pharma LLC | $17.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juliann Wallner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.